When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisión: 18 Mar 2025
Última actualización: 15 Jan 2025

Resumen

Orientación de confianza

ebpracticenet le insta a dar prioridad a las siguientes guías de práctica clínica locales:

Évaluation du risque cardiovasculaire en première lignePublicado por: Domus MedicaPublicado por última vez: 2010Cardiovasculaire risicobepaling in de eerste lijnPublicado por: Domus MedicaPublicado por última vez: 2020

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • presencia de factores de riesgo
  • antecedentes familiares de cardiopatía coronaria o dislipidemia de inicio temprano en parientes de primer grado
  • antecedentes de enfermedad cardiovascular
  • consumo de grasas saturadas y ácidos grasos trans
  • exceso de peso corporal (especialmente obesidad abdominal)
  • xantelasmas
  • xantomas tendinosos

Otros factores de diagnóstico

  • arco senil de la córnea con inicio antes de los 45 años de edad
  • xantomas tuberosos

Factores de riesgo

  • resistencia a la insulina y diabetes mellitus tipo 2
  • exceso de peso corporal (índice de masa corporal > 25 kg/m²)
  • tabaquismo
  • hipotiroidismo.
  • hepatopatía colestásica
  • síndrome nefrótico
  • uso de ciertos medicamentos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • lipidograma
  • hormona estimulante de la tiroides (TSH)
  • lipoproteina (a)

Algoritmo de tratamiento

Colaboradores

Autores

Thorsten Leucker, MD, PhD

Assistant Professor of Medicine

Division of Cardiology, Department of Medicine

Johns Hopkins University School of Medicine

Baltimore

MD

Divulgaciones

TL has received grant funding for his university from Amgen and Merck.

Richard A. Ferraro, MD

Cardiovascular Disease Fellow

Division of Cardiology, Department of Medicine

Johns Hopkins University School of Medicine

Baltimore

MD

Divulgaciones

RAF declares that he has no competing interests.

Agradecimientos

Dr Thorsten Leucker and Dr Richard A. Ferraro would like to gratefully acknowledge Dr Seth S. Martin, Dr Rhanderson Cardoso, Dr Raul D. Santos, Dr Martin Engelhardt, and Dr Michael Miller, the previous contributors to this topic.

Divulgaciones

SSM has received honoraria from the American College of Cardiology for educational activities. SSM is listed as a co-inventor on a pending patent filed by Johns Hopkins University for a novel method of LDL-cholesterol estimation. SSM received a charitable gift for the VLDL big data project from the David and June Trone Family Foundation, and has also received research support from the PJ Schafer Cardiovascular Research Fund, American Heart Association, Aetna Foundation, iHealth, Stanford MedX/Nokia, Google, and Apple. SSM has acted as a consultant for Abbott Nutrition, Pressed Juicery, Quest Diagnostics, Sanofi/Regeneron, Amgen, Novo Nordisk, Esperian, Akcea, and the Pew Institute. RC declares that he has no competing interests. RDS has received honoraria for consulting, speaker activities and research from Astra Zeneca, Amgen, Akcea, Biolab, Esperion, Kowa, Pfizer, Merck, Novo-Nordisk, and Sanofi/Regeneron. ME declares that he has no competing interests. MM has received research grant support and honoraria for lectures from AstraZeneca, Merck-Schering Plough, and Pfizer. MM has received consulting fees from Pfizer, Merck-Schering Plough, and Roche.

Revisores por pares

Mahi Lakshmi Ashwath, MD

Assistant Professor of Medicine

Noninvasive Cardiology

MetroHealth Campus

Case Western Reserve University

Cleveland

OH

Divulgaciones

MLA declares that he has no competing interests.

Deepak Bhatnagar, TD MBBS PhD FRCP FRCPI FRCPath

Consultant/Senior Lecturer in Diabetes & Metabolism

The Royal Oldham Hospital & University of Manchester Cardiovascular Research Group Diabetes Centre

Royal Oldham Hospital

Oldham

UK

Divulgaciones

DB declares that he has no competing interests.

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad